Health and Healthcare

Amarin Takes on More Debt, Shares Suffer

pills
Thinkstock
Biopharmaceutical company Amarin Corp. PLC (NASDAQ: AMRN) announced after markets closed last night that it has received $100 million in nonequity financing from an investment fund managed by Pharmakon Advisors. Calling the cash infusing a “hybrid debt-like instrument,” the drug maker implied that the funds will be spent to hire a sales force of 250 to 300, all of whom are expected to have three to five years experience selling to the physician groups that Amarin has targeted for its new heart drug, Vascepa.

At the end of the September quarter, Amarin held cash and equivalents of just over $215 million and long-term debt of about $222 million. The cash from the Pharmakon deal will be paid back over three and half years, beginning in November 2013 and continuing through 2017.

Amarin simply did not have the wherewithal to launch its new drug on its own and needed a partner. Now that it has got one, investors are squeamish about the company’s ability to market Vascepa successfully. The company is still exploring strategic options, including a possible sale of the company. Not good for existing investors.

Shares are down nearly 20% in premarket trading today, at $9.58 in a 52-week range of $5.99 to $15.96. Short interest in the stock totals nearly 20 million shares. There are some happy folks out there today.

Paul Ausick

The #1 Thing to Do Before You Claim Social Security (Sponsor)

Choosing the right (or wrong) time to claim Social Security can dramatically change your retirement. So, before making one of the biggest decisions of your financial life, it’s a smart idea to get an extra set of eyes on your complete financial situation.

A financial advisor can help you decide the right Social Security option for you and your family. Finding a qualified financial advisor doesn’t have to be hard. SmartAsset’s free tool matches you with up to three financial advisors who serve your area, and you can interview your advisor matches at no cost to decide which one is right for you.

Click here to match with up to 3 financial pros who would be excited to help you optimize your Social Security outcomes.

 

Have questions about retirement or personal finance? Email us at [email protected]!

By emailing your questions to 24/7 Wall St., you agree to have them published anonymously on a673b.bigscoots-temp.com.

By submitting your story, you understand and agree that we may use your story, or versions of it, in all media and platforms, including via third parties.

Thank you for reading! Have some feedback for us?
Contact the 24/7 Wall St. editorial team.